EUCTR2022-002312-23-CZ招募中1 期
A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 524
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria are met:
- •1. Participant is = 55 to = 90 years of age inclusive (upper age limit of 75 years inclusive, for participants in Czech Republic only), at the time of signing the informed consent.
- •2. Participant is an ambulatory postmenopausal woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause).
- •- Serum FSH test can be done at the Screening Visit in case of uncertainty
- •- Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.
- •3. Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of = -2.5 and = -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.
- •4. Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit.
- •5. Participant has body weight = 50 kg and = 90 kg at Screening.
- •6. Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 399
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 125
排除标准
- •Participants are excluded from the study if any of the following criteria are met:
- •1. Participant has a history of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.
- •2. Participant has a history and/or presence of hip fracture.
- •3. Participant has a history and/or presence of atypical femur fracture.
- •4. Participant presents with any active healing fracture, per assessment of the Investigator.
- •5. Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).
- •6. Participant has history and/or presence of osteonecrosis of the external auditory canal.
- •7. Evidence of any of the following conditions which may affect BMD or interfere with the interpretation of the findings:
- •a. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget’s disease, or osteogenesis imperfecta.
- •b. Participant has a history of metabolic or other endocrinologic diseases such as Cushing’s disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn’s disease and chronic pancreatitis).
- •c. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities.
- •d. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non-clinically significant secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor.
- •e. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note: Participants with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria:
- •If TSH level is within normal range, the participant is eligible.
- •If TSH level is elevated (> upper limit of normal and = 10.0 µIU/mL) and serum free T4 is within normal range, the participant is eligible.
- •If a marginally low TSH level results from the therapy, the participant may be enrolled after discussion with the Medical Monitor. Note: 2) If TSH is marginally out of normal range, serum free T4 is within normal range, and there are no plausible medical conditions resulting in abnormal TSH level, the participant may be enrolled with the
- •approval from the Medical Monitor.
- •f. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone metastases, renal osteodystrophy, osteomyelitis).
- •8. Participant has hypocalcemia (defined as albumin adjusted serum calcium level < 2.0 mmol/L [8.0 mg/dL] or hypercalcemia (defined as albumin adjusted serum calcium levels > 2.62 mmol/L [10.50 mg/dL]).
- •9. Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level < 20 ng/mL
- •[< 50 nmol/L]).
- •Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level = 20 ng/mL (= 50 nmol/L).
- •10. Participant has any malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
- •11. Participant has known history of liver cirrhosis.
研究者
相似试验
未知
不适用
A randomized, double-blind, parallel-group, active-controlled, multi-center study to evaluate the long-term safety and efficacy of combination of solifenacin succinate with mirabegron compared to solifenacin succinate and mirabegron in subjects with overactive bladder-N31N31PER-046-14Astellas Pharma Europe B.V,
招募中
1 期
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosisPostmenopausal osteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2022-002312-23-BGShandong Boan Biotechnology Co., Ltd.524
进行中（未招募）
1 期
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression ( VIVRE )Major depressive disorderMedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2019-002704-41-EEH. Lundbeck A/S600
进行中（未招募）
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.-Major Depressive Disorder (MDD)MedDRA version: 14.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 100000004873EUCTR2011-002362-21-CZH. Lundbeck A/S500
进行中（未招募）
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.EUCTR2011-002362-21-GBH. Lundbeck A/S500